Dinesh Vannan, Director, Marketing, Rare Disease Portfolio, Chiesi Global Rare Diseases
Dinesh Vannan has been at the forefront of some of Chiesi Global Rare Diseases’ most recent launch achievements. One example is Lamzede (velmanase alfa-tycv), the first and only enzyme replacement therapy (ERT) for patients with alpha-mannosidosis. Prior to Lamzede, the only treatment option for this ultra-rare disease was potential eligibility for hematopoietic stem cell transplant (HSCT) for patients who were diagnosed before the age of 3 and matched with an appropriate donor.
Dinesh orchestrated the development of impactful creative and messaging to demonstrate that Lamzede can enable small but measurable differences in patients’ daily lives. By providing the field force with engaging materials to bring the brand story to life, Dinesh helped encourage clinical recognition of alpha-mannosidosis and earlier patient identification and treatment initiation.
He also helped to create dialogue and a supportive community in a space with no specific advocacy groups and a lack of specialists. While estimates of alpha-mannosidosis vary, as few as 80 diagnosed patients may be in the U.S. By Q3 2023, over a dozen patients will receive Lamzede. Lives are being revolutionized through Dinesh’s tireless efforts to bring recognition and viable treatment to this ultra-rare community.
In parallel, Dinesh leads the HCP marketing efforts for Elfabrio (pegunigalsidase alfa-iwxj), the PEGylated ERT formulation for Fabry Disease. Since 1 in 500 patients on dialysis could have Fabry, he championed a renal resource for nephrologists that provides information on the hidden impact of Fabry on kidneys. His dedication is making a real difference in the lives of families living with Fabry and alpha-mannosidosis.
